Digital partnerships focused on drug discovery and development drive future growth potential

DUBLIN, August 10, 2022 /PRNewswire/ — The “Global Pharmaceutical Tracker, 2022” report has been added to from offer.

This research service offers in-depth discussions of the major pharmaceutical industry approvals, mergers and acquisitions, product licensing agreements and digital partnerships in 2022.

A renewed focus on operational excellence and digital transformation will drive growth in the pharma industry and generate strong partnerships with small and midsize pharma and digital solution providers.

The digital implosion is transforming the pharmaceutical business model to achieve digital maturity. Big pharma is moving towards partnerships with technology vendors to accelerate digitization and reduce the risk of investments in in-house capabilities, platforms and solutions.

Shrinking R&D pipelines, stagnating productivity over the past 2 decades, and disruption of clinical trials due to the pandemic have led to an increase in partnerships. Small and medium enterprises will continue to attract big pharma and private equity (PE) firms.

New terms and technologies will remain attractive for licensing agreements, giving would-be biotech licensors a greater chance to negotiate contract terms and upfront payments.

Main topics covered:

1. Summary

  • Highlights
  • Pharmaceutical Industry – Companies to Watch

2. Approvals of new terms, Q1 2022

3. Mergers and acquisitions, Q1 2022

4. Major Licensing and Licensing Agreements, Q1 2022

5. Main digital partnerships, Q1 2022

For more information about this report visit

Media Contact:

Research and Markets
Laura Woodsenior
[email protected]

For EST office hours, call +1-917-300-0470
For USA/CAN call toll free +1-800-526-8630
For GMT office hours call +353-1-416-8900

US Fax: 646-607-1907
Fax (outside the US): +353-1-481-1716


SOURCE Research and Markets